7.2.5.5	  Summary of evidence and recommendations for neoadjuvant and adjuvant therapy,
Recommendations,Strength rating
Do not perform cytoreductive nephrectomy (CN) in MSKCC poor-risk patients.,Strong
Do not perform immediate CN in intermediate-risk patients who have an asymptomatic   synchronous primary tumour and require systemic therapy.,Weak
Start systemic therapy without CN in intermediate-risk patients who have an asymptomatic   synchronous primary tumour and require systemic therapy.,Weak
